A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita

Exclusion Criteria

• •Females who are pregnant or breastfeeding
• •Concomitant use of sirolimus or any sirolimus-containing medications (systemic or topical)
• •Any significant concurrent condition that could adversely affect participation and/or the assessment of the safety and efficacy in the study
• •Prior or planned treatment, including surgery or other medically necessary intervention deemed by the investigator that could adversely affect participation and/or the assessment of the safety and efficacy in the study